Clinical trial PACIFIC R
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy - PACIFIC Real World, PACIFIC-R
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Trial type |
Prospective observational study
|
| Phase | Trial phase 4 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| BECT Identifier | B707201939523 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03798535 |
| Inclusion criteria | Advanced, recurrent, ou unresecable |
| Last update |